Cook Biotech, Inc.

Cook Incorporated

Med Institute Incorporated

Cook Medical Technologies LLC

Lal Ninan

Jason P Hodde

Michael C Hiles

Jichao Sun

David M J Ernst

Neal E Fearnot

Thomas A Osborne

Alan R Leewood

Michael P DeBruyne

Jason A Mead

Clinton D Bahler

Joel A Virkler

Sherry L Voytik-Harbin

Bhavin Shah

David Douglas Grewe

James D Purdy

Kurt Dierking

David Mj Ernst

Nathan Hammond

Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.

Graft materials containing bioactive substances, and methods for their manufacture

Described are embolization devices having unique bioactive coatings, as well as methods for their manufacture and use. An illustrative embolization device of the invention comprises an embolic body and a coating material comprising biotropic extracellular matrix material immobilized on a surface of the embolic body. The biotropic extracellular matrix material comprises a network of self-assembled collagen fibrils, and comprises at least one bioactive agent retained in the extracellular matrix material, wherein the bioactive agent is selected from the group consisting of a proteoglycan, a growth factor, a glycoprotein, and a glycosaminoglycan. In certain forms, such an extracellular matrix material comprises a remodelable, angiogenic extracellular matrix material, for example, a submucosa material such as but not limited to porcine small intestinal submucosa.

Coated embolization device

Graft materials containing ECM components, and methods for their manufacture

Described, in certain aspects, are medical products comprised of uniquely prepared remodelable extracellular matrix (ECM) materials retaining at least a portion of their native bioactivity. Also described are methods for forming and using such products. In one embodiment, an inventive product comprises a layer of remodelable ECM material modified through contact with periodic acid or a salt thereof. In some forms, such a modified ECM material layer includes non-native Schiff's base crosslinks within and/or between certain components of the ECM material (e.g., between two collagen molecules, two non-collagen molecules, and/or a collagen molecule and a non-collagen molecule). Other inventive products are comprised of various gels, foams, pastes, and formed, coherent, porous bodies at least containing ECM materials that have been modified in accordance with the present invention.

Medical products including modified extracellular matrix materials

This invention is directed to graft materials for implanting, transplanting, replacing, or repairing a part of a patient and to methods of making the graft materials. The present invention is also directed to stent grafts and endoluminal prostheses formed of the graft materials. More specifically, the present invention is a graft material which includes porous polymeric sheet, extracellular matrix material (ECM) disposed on at least a portion of the porous polymeric sheet and at least one polymer layer disposed on at least a portion of the ECM. The ECM may be in a gel form. The polymeric sheet and the polymer layer may be made from foam material and may comprise a polyurethane urea and a surface modifying agent such as siloxane.

Graft material, stent graft and method

Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibrob-last Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.

An endoluminal device comprises a stent and a tubular graft supported by the stent. The graft has a proximal and a distal opening and comprises a synthetic material and a bioremodelable material. The bioremodelable material is disposed on an exterior surface in at least one band adjacent at least one of the proximal and distal openings.

Endoluminal device with extracellular matrix material and methods

Growing community of inventors

Santa Rosa, CA, United States of America

Lal Ninan